Therapeutic potential of N-acetyl cysteine during COVID-19 epoch

N-acetyl cysteine (NAC) is a promising drug for prophylaxis and treatment of coronavirus disease 2019 (COVID-19) based on antioxidant and anti-inflammatory mechanisms. Further studies with cautious approach are needed to establish the benefits and risks before considering NAC as an adjuvant treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Kapur, Ajita, Sharma, Munish, Sageena, Geetanjali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8966593/
https://www.ncbi.nlm.nih.gov/pubmed/35433335
http://dx.doi.org/10.5501/wjv.v11.i2.104
_version_ 1784678673374248960
author Kapur, Ajita
Sharma, Munish
Sageena, Geetanjali
author_facet Kapur, Ajita
Sharma, Munish
Sageena, Geetanjali
author_sort Kapur, Ajita
collection PubMed
description N-acetyl cysteine (NAC) is a promising drug for prophylaxis and treatment of coronavirus disease 2019 (COVID-19) based on antioxidant and anti-inflammatory mechanisms. Further studies with cautious approach are needed to establish the benefits and risks before considering NAC as an adjuvant treatment for COVID-19.
format Online
Article
Text
id pubmed-8966593
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-89665932022-04-14 Therapeutic potential of N-acetyl cysteine during COVID-19 epoch Kapur, Ajita Sharma, Munish Sageena, Geetanjali World J Virol Letter to the Editor N-acetyl cysteine (NAC) is a promising drug for prophylaxis and treatment of coronavirus disease 2019 (COVID-19) based on antioxidant and anti-inflammatory mechanisms. Further studies with cautious approach are needed to establish the benefits and risks before considering NAC as an adjuvant treatment for COVID-19. Baishideng Publishing Group Inc 2022-03-25 2022-03-25 /pmc/articles/PMC8966593/ /pubmed/35433335 http://dx.doi.org/10.5501/wjv.v11.i2.104 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Letter to the Editor
Kapur, Ajita
Sharma, Munish
Sageena, Geetanjali
Therapeutic potential of N-acetyl cysteine during COVID-19 epoch
title Therapeutic potential of N-acetyl cysteine during COVID-19 epoch
title_full Therapeutic potential of N-acetyl cysteine during COVID-19 epoch
title_fullStr Therapeutic potential of N-acetyl cysteine during COVID-19 epoch
title_full_unstemmed Therapeutic potential of N-acetyl cysteine during COVID-19 epoch
title_short Therapeutic potential of N-acetyl cysteine during COVID-19 epoch
title_sort therapeutic potential of n-acetyl cysteine during covid-19 epoch
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8966593/
https://www.ncbi.nlm.nih.gov/pubmed/35433335
http://dx.doi.org/10.5501/wjv.v11.i2.104
work_keys_str_mv AT kapurajita therapeuticpotentialofnacetylcysteineduringcovid19epoch
AT sharmamunish therapeuticpotentialofnacetylcysteineduringcovid19epoch
AT sageenageetanjali therapeuticpotentialofnacetylcysteineduringcovid19epoch

Ejemplares similares